The HeartWare cannula has shown roughness of 8.0 and 6.1 μm for the internal and the external surfaces, respectively. In contrast, the HeartMate II cannula showed a 374.3 μm roughness in both surfaces.
As a general indication, the Ti alloy used to manufacture the VAD cannulas is the Ti6Al4V alloy approved from the FDA. The thermal treatments used to fabricate and model the inflow cannulas are responsible of some metal segregation that modifies the composition of the cannula surfaces. In addition, also the Ti6Al4V alloy can contain other metals in low concentrations that, because of the thermodynamic surface segregation phenomenon, can be evidenced only with a surface-sensitive technique (XPS).
The XPS atomic concentration analysis of the HeartWare internal cannula reveals increased Si and Al surface concentrations Si/Ti = 0.41 and Al/Si = 0.14 as compared to the HeartMate II. No Si presence was observed with EDX analyses in both HeartMate II and HeartWare cannulas. Therefore, the Si presence is confined to the topmost surface layers. Titanium is present only as TiO2 on the surface.27,28 In addition, a small but evident presence of lead, Pb/Ti = 0.01, was also found on the internal surface (Figure 7A) with the Pb 4f7/2 and Pb 4f5/2 spin–orbit components at 138.5 and 143.4 eV, respectively, and typical of the PbO phase.29
Our study is the first addressing the physicochemical characterization of LVADs’ surfaces with techniques that allow high vertical resolution, providing information on the bonding states of molecules and on the elemental composition of the surfaces; moreover, morphological and quantitative results have been obtained.
Thromboembolic complications may result from ingestion of thrombi grown around the inflow cannula at the implant site in the left ventricle, especially in the presence of stasis or suction.
To improve the biocompatibility of the foreign material, pseudo-endothelial artificial surfaces have been implemented in LVADs. Two major groups of coating can be distinguished: bioactive (heparin, nitric oxide) and biopassive (albumin, phosphorylcholine). Heparin interferes with the physiological hemostasis but the duration of the immobilized heparin on the surfaces of the LVAD is not known over the time and phenomena of superficial thrombosis are often observed on LVAD surfaces and no consistent benefits of coating of artificial surfaces has yet been shown.
Few data are available on the role of the physicochemical properties of foreign surfaces and thrombosis: Ellingensen27 reported that oxide layers increase the surface hydrophobicity thus causing greater adsorption of proteins. In contrast to this view, other authors indicated an increased compatibility of blood with the titania layer.28
Our study has shown major differences between the HeartWare and HeartMate II. First, as far as the external surfaces, its roughness is much more pronounced for the HeartMate II device. Moreover, the HeartMate II cannula is totally covered with Ti nanospheres, while the HeartWare cannula shows only the lower external aspect covered with Ti sintered microspheres. In addition, the internal surfaces of the cannulas of these two devices are totally different: in fact, the HeartWare system shows no Ti microspheres and the surface roughness is ~8.0 μm while the HeartMate II cannula showed a ~374 μm roughness in both surfaces. Furthermore, no heparin was observed on the internal surface of the HeartMate II device.
In the light of these data, the HeartMate II and HeartWare LVAD have major differences in the physicochemical characteristics of their inflow cannula, albeit both sintered with titanium microspheres; whether these turn into major clinical outcomes warrants further studies. Structural inflow cannula changes and improvements of biocompatibility might turn into pivotal positive results in the clinical setting.
The combination of the analytical techniques applied in this study is unique in this field and could play interesting in evaluating innovations in structural changes and biocompatibility of artificial surfaces.
In conclusion, this is the first study addressing the physicochemical characteristics of LVADs. Both HeartWare and HeartMate II LVADs show sintered titanium microspheres on the inflow cannulas. The two surfaces are, however, significantly different both macroscopically (in terms of design of the inner and outer side of the cannula and of smooth and rough surfaces) and microscopically (sintering of titanium microspheres). In both HeartWare and HeartMate II inflow cannulas the surface titanium is present as TiO2 with no zero-valent Ti. In the light of these data, further studies are warranted to address the interaction of the artificial surfaces of LVADs and blood coagulation, their correlations with thromboembolic complications, and eventually the optimization of anticoagulation.
A. Gulino and F. Pappalardo thank INSTM and Regione Lombardia for the financial support of the BIOSUOVAD project, 2013. A. Gulino thanks the University of Catania. The authors are indebted to O. G. Turla, CCP, for his continuous support and for data collection.
1. Potapov EV, Stepanenko A, Krabatsch T, Hetzer R. Managing long-term complications of left ventricular assist device
therapy. Curr Opin Cardiol. 2011;26:237–244
2. Slaughter MS, Pagani FD, Rogers JG, et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart
failure. J Heart
Lung Transplant. 2010;29:S1–S39
3. Backes D, van den Bergh WM, van Duijn AL, Lahpor JR, van Dijk D, Slooter AJ. Cerebrovascular complications of left ventricular assist devices. Eur J Cardiothorac Surg. 2012;42:612–620
4. John R, Kamdar F, Liao K, et al. Low thromboembolic risk for patients with the Heartmate II left ventricular assist device
. J Thorac Cardiovasc Surg. 2008;136:1318–1323
5. Menon AK, Götzenich A, Sassmannshausen H, Haushofer M, Autschbach R, Spillner JW. Low stroke rate and few thrombo-embolic events after HeartMate II implantation under mild anticoagulation. Eur J Cardiothorac Surg. 2012;42:319–323; discussion 323
6. Adzic A, Patel SR, Maybaum S. Impact of adverse events on ventricular assist device outcomes. Curr Heart
Fail Rep. 2013;10:89–100
7. Yuan N, Arnaoutakis GJ, George TJ, et al. The spectrum of complications following left ventricular assist device
placement. J Card Surg. 2012;27:630–638
8. Reilly MP, Wiegers SE, Cucchiara AJ, et al. Frequency, risk factors, and clinical outcomes of left ventricular assist device
-associated ventricular thrombus. Am J Cardiol. 2000;86:1156–1159
9. Rose EA, Gelijns AC, Moskowitz AJ, et al.Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart
Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device
for end-stage heart
failure. N Engl J Med. 2001;345:1435–1443
10. Radovancevic B, Vrtovec B, de Kort E, Radovancevic R, Gregoric ID, Frazier OH. End-organ function in patients on long-term circulatory support with continuous- or pulsatile-flow assist devices. J Heart
Lung Transplant. 2007;26:815–818
11. Slaughter MS, Rogers JG, Milano CA, et al.HeartMate II Investigators. Advanced heart
failure treated with continuous-flow left ventricular assist device
. N Engl J Med. 2009;361:2241–2251
12. John R, Kamdar F, Eckman P, et al. Lessons learned from experience with over 100 consecutive HeartMate II left ventricular assist devices. Ann Thorac Surg. 2011;92:1593–1599; discussion 1599
13. Pagani FD, Miller LW, Russell SD, et al.HeartMate II Investigators. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device
. J Am Coll Cardiol. 2009;54:312–321
14. Eckman PM, John R. Bleeding and thrombosis
in patients with continuous-flow ventricular assist devices. Circulation. 2012;125:3038–3047
15. Pepper JR. Update on mechanical circulatory support in heart
16. Backes D, van den Bergh WM, van Duijn AL, Lahpor JR, van Dijk D, Slooter AJ. Cerebrovascular complications of left ventricular assist devices. Eur J Cardiothorac Surg. 2012;42:612–620
17. Erbulut DU, Lazoglu I.Lysaght M, Webster TJ. Biomaterials for improving the blood and tissue compatibility of total artificial hearts (TAH) and ventricular assist devices (VAD). Biomaterials for Artificial Organs. 2011 Oxford WPL:207–235
18. Gulino A. Structural and electronic characterization of self-assembled molecular nanoarchitectures by X-ray photoelectron spectroscopy
. Anal Bioanal Chem. 2013;405:1479–1495
19. Briggs D, Grant JT Surface Analysis by Auger and X-Ray Photoelectron Spectroscopy
. 2003 Chichester IMP
20. Gulino A, Egdell RG, Fragalà I. Low-temperature stabilization of tetragonal zirconia by antimony. J Mater Chem. 1996;6:1805–1809
21. Gulino A, La Delfa S, Fragalà I, Egdell RG. Low-temperature stabilization of tetragonal zirconia by bismuth. Chem Mater. 1996;8:1287–1291
22. Jing FJ, Wang L, Fu RKY, et al. Behavior of endothelial cells on micro-patterned titanium oxide fabricated by plasma immersion ion implantation and deposition and plasma etching. Surf Coatings Technol. 2007;201:6874–6877
23. Graham TR, Dasse K, Coumbe A, et al. Neo-intimal development on textured biomaterial surfaces during clinical use of an implantable left ventricular assist device
. Eur J Cardiothorac Surg. 1990;4:182–190
24. Gulino A, Taverner AE, Warren S, Harris P, Egdell RG. A photoemission study of Sb-doped TiO2
. Surf Sci
25. Gulino A, Condorelli GG, Fragalà I, Egdell RG. Surface segregation of Sb in doped TiO2
rutile. App Surf Sci. 1995;90:289–295
26. Kotsis I, Kristof-Mako E, Gulino A, Fragalà I. Novel results in the characterisation of the plasma-sprayed titanium coating of endosseous implant. Hung J Ind Chem. 1999;27:149–153
27. Ellingensen JE. A study on the mechanism of protein adsorption to TiO2
. Biomaterials. 1991;12:593–596
28. Huang N, Yang P, Leng YX, et al. Hemocompatibility of titanium oxide films. Biomaterials. 2003;24:2177–2187
29. Osaka A, Wang YH, Miura Y, Tsugaru T. X–ray photoelectron spectroscopy of lead fluorosilicate glasses. J Mater Sci. 1991;26:2778–2782
30. Drews T, Loebe M, Hennig E, Kaufmann F, Müller J, Hetzer R. The ‘Berlin Heart
’ assist device. Perfusion. 2000;15:387–396
31. Aaronson KD, Slaughter MS, Miller LW, et al.HeartWare Ventricular Assist Device (HVAD) Bridge to Transplant ADVANCE Trial Investigators. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart
transplantation. Circulation. 2012;125:3191–3200
32. Slaughter MS, Pagani FD, McGee EC, et al.HeartWare Bridge to Transplant ADVANCE Trial Investigators. HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. J Heart
Lung Transplant. 2013;32:675–683
33. Starling RC, Moazami N, Silvestry SC, et al. Unexpected abrupt increase in left ventricular assist device thrombosis
. N Engl J Med. 2014;370:33–40